ArticleInternational journal of nanomedicine2011
Oral fondaparinux: use of lipid nanocapsules as nanocarriers and in vivo pharmacokinetic study.
Article in International journal of nanomedicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Prophylactic effect of nano vitamin D3 against fatty degeneration caused by calcium-deficient diet in parotid salivary gland: a histological and ultrastructural study.BMC oral health · 2025Article
- Specific quantification of intact lipid nanocapsules in rats using FRET: biodistribution and PBPK model development.Nanomedicine (London, England) · 2025Article
- Histopathological, physiological and biochemical assessment of resveratrol nanocapsules efficacy in bleomycin-induced acute and chronic lung injury in rats.Drug delivery · 2022Article
- Review
- New In Vitro Coculture Model for Evaluating Intestinal Absorption of Different Lipid Nanocapsules.Pharmaceutics · 2021Article
- Current approaches in lipid-based nanocarriers for oral drug delivery.Drug delivery and translational research · 2021Review
- Cyclosporine Lipid Nanocapsules as Thermoresponsive Gel for Dry Eye Management: Promising Corneal Mucoadhesion, Biodistribution and Preclinical Efficacy in Rabbits.Pharmaceutics · 2021Article
- Modified Lipid Nanocapsules for Targeted Tanshinone IIA Delivery in Liver Fibrosis.International journal of nanomedicine · 2021Article
- Advanced delivery strategies facilitating oral absorption of heparins.Asian journal of pharmaceutical sciences · 2020Review
- Development of Lipid-Polymer Hybrid Nanoparticles for Improving Oral Absorption of Enoxaparin.Pharmaceutics · 2020Article
- Praziquantel-lipid nanocapsules: an oral nanotherapeutic with potentialInternational journal of nanomedicine · 2018Article
- Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia.International journal of nanomedicine · 2017Article
- Miltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical Study.PloS one · 2015Article
- Cationic additives in nanosystems activate cytotoxicity and inflammatory response of human neutrophils: lipid nanoparticles versus polymeric nanoparticles.International journal of nanomedicine · 2015Article
- Novel self assembling nanoparticles for the oral administration of fondaparinux: synthesis, characterization and in vivo evaluation.Journal of controlled release : official journal of the Controlled Release Society · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral anticoagulant therapy could be advanced using lipid-based nanoparticulate systems. This study examined lipid nanocapsules for their oral absorption potential as the first step in developing oral fondaparinux (Fp) novel carriers. Using phase inversion method and cationic surfactants such as hexadecyltrimethyl ammonium bromide (CTAB) or stearylamine (SA), cationic lipid nanocapsules (cLNCs), loaded with Fp on their surface, were prepared and characterized (zeta potential, size and Fp association efficiency and content). In vivo studies were conducted after single oral increasing doses of Fp-loaded cLNCs (0.5 to 5 mg/kg of Fp) in rats and the concentration of Fp in the plasma was measured by anti-factor Xa activity assay. The monodisperse, (~50 nm), positively charged Fp-cLNCs with high drug loadings demonstrated linear pharmacokinetic profiles of the drug with an increased oral absolute bioavailability (up to ~21%) compatible with therapeutic anticoagulant effect (>0.2 μg/mL).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.